Stefan Habringer

8PUBLICATIONS
59CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 26, 2025
The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma.

Kaiting Jiang, Marieluise Kirchner, Frederik Herzberg

|Jun 17, 2024
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass.

Stefan Habringer, Jana Ihlow, Karsten Kleo

|Aug 18, 2023
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Jonas S Heitmann, Claudia Tandler, Maddalena Marconato

|Feb 24, 2022
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.

Josefina Doffo, Stefanos A Bamopoulos, Hazal Köse

|Jan 13, 2022
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.

Markus Schick, Le Zhang, Sabine Maurer

|Aug 07, 2021
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Richard Lewis, H Carlo Maurer, Nikita Singh

Pageof 2

Frequent Collaborators

7 joint publications

Ulrich Keller

5 joint publications

Matthias Wirth

2 joint publications

Richard Lewis

2 joint publications

Marieluise Kirchner